AstraZeneca to halt Cefotan sales
Executive Summary
AstraZeneca will discontinue sales of the injectable antibiotic Cefotan after current inventory is depleted in March 2006. Bulk active ingredient supplier Astellas (formerly Yamanouchi) has stopped production of cefotetan, as has sterile end product manufacturer GlaxoSmithKline, AstraZeneca says. The company began notifying hospitals and wholesaler customers two years ago about the pending inventory depletion and potential therapeutic alternatives, including Merck's Mefoxin (cefoxitin). Cefotan global net sales in 2004 were $39.6 mil., with most of those in the U.S, AstraZeneca notes...
You may also be interested in...
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: